research compound is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-03-03. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ in preclinical models |
| Molecular formula | C20H24ClN3O4S | Reported for the parent compound |
| CAS Registry Number | 1379686-30-2 | Common identifier in chemical databases |
| Appearance | Off-white to pale yellow solid | Typical research chemical solid |
| Solubility | Soluble in DMSO and ethanol; low in water | Class: small organic molecule |
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
The conflict introduced live news broadcasts from the front lines of the battle, principally by American network CNN. It earned the nickname "Video Game War", after the daily broadcast of images from cameras onboard American military aircraft. The war highlighted new military technologies including military satellites, precision-guided munitions and a stealth aircraft, the F-117 Nighthawk. The largest tank battles in American military history were also fought, surpassed only by the Battle of the Bulge: the Battle of Medina Ridge, the Battle of Norfolk, and the Battle of 73 Easting.
=== Release mechanism === Peptide's release occurs primarily in a calcium-dependent manner through exocytosis of large dense core vesicles in the presynaptic terminal. Big dynorphin immunoreactivity has been detected in regions such as the nucleus accumbens, caudate nucleus, and hippocampus, with significant levels detected in cerebrospinal fluid. The ratio of big dynorphin to dynorphin B in human brain tissue is approximately 1:3.
==== Breast surgery ==== Breastfeeding can generally be attempted after breast augmentation or reduction surgery; however, prior breast surgery is a risk factor for low milk supply. A 2014 review found that women who have breast implant surgery were less likely to breastfeed exclusively; however, it was based on only three small studies, and the reasons for the correlation were not clear. A large follow-up study done in 2014 found a reduced rate of breastfeeding in women who had undergone breast augmentation surgery; however, again, the reasons were unclear. The authors suggested that women contemplating augmentation should be provided with information related to the rates of successful breastfeeding as part of informed decision-making when contemplating surgery. Prior breast reduction surgery is strongly associated with an increased probability of low milk supply due to disruption to tissues and nerves. Some surgical techniques for breast reduction appear to be more successful than others in preserving the tissues that generate and channel milk to the nipple. A 2017 review found that women were more likely to have success with breastfeeding with these techniques.
The largest risk of relapse occurs within the first year post-discharge from eating disorder therapy treatment. Within the first two years post-discharge, approximately 31% of anorexia nervosa patients relapse. Many complications, both physical and psychological, improve or resolve with nutritional rehabilitation and adequate weight gain. Anorexia nervosa is estimated to occur in approximately 0.3–4.3% of women and 0.2–1% of men in Western countries at some point in their life. Levels in other countries are unclear due to undiagnosis and a lack of awareness, though it can be presumed it is more present in Western societies due to a higher focus on low body weight and beauty on social media and real life. There is an observation for an increase in the diagnosis of anorexia from the 20th century onwards: it is unclear whether this is due to an actual increase in its frequency or simply due to improved diagnostic capabilities. In 2013, it directly resulted in about 600 deaths globally, up from 400 deaths in 1990. Eating disorders also increase a person's risk of death from a wide range of other causes, including suicide. About 5% of people with anorexia die from complications over a ten-year period with medical complications and suicide being the primary and secondary causes of death respectively. Anorexia has one of the highest death rates among mental illnesses, second only to opioid overdoses.
Sources: en.wikipedia.org
Anemia Insufficient red cell mass (anemia) can be the result of bleeding, blood disorders like thalassemia, or nutritional deficiencies, and may require one or more blood transfusions. Anemia can also be due to a genetic disorder in which the red blood cells do not function effectively. Anemia can be confirmed by a blood test if the hemoglobin value is less than 13.5 gm/dl in men or less than 12.0 gm/dl in women. Several countries have blood banks to fill the demand for transfusable blood. A person receiving a blood transfusion must have a blood type compatible with that of the donor. Sickle-cell anemia Disorders of cell proliferation Leukemia is a group of cancers of the blood-forming tissues and cells. Non-cancerous overproduction of red cells (polycythemia vera) or platelets (essential thrombocytosis) may be premalignant. Myelodysplastic syndromes involve ineffective production of one or more cell lines. Disorders of coagulation Hemophilia is a genetic illness that causes dysfunction in one of the blood's clotting mechanisms. This can allow otherwise inconsequential wounds to be life-threatening, but more commonly results in hemarthrosis, or bleeding into joint spaces, which can be crippling. Ineffective or insufficient platelets can also result in coagulopathy (bleeding disorders). Hypercoagulable state (thrombophilia) results from defects in regulation of platelet or clotting factor function, and can cause thrombosis. Infectious disorders of blood Blood is an important vector of infection.
Immediate untreated crush syndrome death is caused by severe head injury, torso injury with damaged abdominal organs, and asphyxia (excessive loss of oxygen). Early untreated crush syndrome death is caused by hyperkalemia and by hypovolemic shock. Late untreated crush syndrome death is caused by renal failure, coagulopathy and hemorrhage, and sepsis. Due to the risk of crush syndrome, current recommendation to nonprofessional first-aiders (in the UK) is to not release those with a crush injury who have been trapped for more than 15 minutes. A torniquet may be used in the event that treatment is not immediately available, as it traps toxins in the ischemic limb, but it is only a method of postponing medical attention. Upon release, isotonic saline is used for fluid resuscitation.
Sheikh Sāleḥ bin Fawzān bin ‘Abd Allāh al-Fawzān (born 28 September 1935) is a Saudi Islamic scholar who is the fourth and current Grand Mufti of Saudi Arabia, serving since 22 October 2025. He is regarded as one of the senior scholars within the Salafi movement. Al-Fawzan is also a member of Saudi Arabia's Council of Senior Scholars and the fiqh council in Mecca, affiliated with the Muslim World League. He also serves as a member of the Supervisory Committee for Preachers during Hajj, and a member of the Permanent Committee for Scholarly Research and Ifta in the Saudi Arabia. In addition to this, he is an imam, khatib and teacher at the Prince Mutaib bin Abdulaziz Al Saud Mosque in Riyadh. He participates in the radio program Nūr 'Alā al-Darb, answering questions on Islamic topics, and contributes to scholarly journals in the form of research, studies, letters, and fatwas.
Sources: en.wikipedia.org
=== In antiquity === Emperor Ashoka, who ruled the Maurya Empire in the Indian subcontinent from 269 to 232 BCE, abolished the slave trade but not slavery. The Qin dynasty, which ruled China from 221 to 206 BCE, abolished slavery and discouraged serfdom. However, many of its laws were overturned when the dynasty was overthrown. Slavery was again abolished by Wang Mang in China in 17 CE but was reinstituted after his assassination.
== Environment == Dumping plastic waste: Thailand ranked sixth of 192 nations with ocean shorelines (1=worst, 192=best). Based on 2010 data, Thailand is estimated to have contributed 1.03 million tonnes of plastic waste to the ocean. The 10 biggest marine polluters (by millions of tonnes of plastic waste dumped in the ocean each year) are: China 8.8; Indonesia 3.2; The Philippines 1.9; Vietnam 1.8; Sri Lanka 1.6; Thailand 1.0; Egypt 1.0; Nigeria 0.9; Malaysia 0.9; and Bangladesh 0.8 Environmental Performance Index 2016: Thailand was ranked 91 of 180 nations (1=best, 180=worst) for its performance on environmental issues. Other ASEAN nations were ranked: Singapore, 14; Malaysia, 63; Philippines, 66; Brunei, 98; Indonesia, 107; Vietnam, 131; Cambodia, 146; Laos, 148; and Myanmmar, 153. Environmental Sustainability Index 2005: Ranked 73 of 146 countries. Fish species, threatened: Of 215 nations, Thailand ranked 12 (1=worst, 215=best) in fish species at risk (96 species) in 2014. ASEAN member-states ranked from number five (Indonesia) to 175 (Brunei). Mammal species, threatened: Of 214 countries studied, Thailand ranks ninth (1=worst, 214=best) in the world in the number of mammal species (55 species) under threat. ASEAN nations fared poorly in this study: Indonesia was number one on the world list with 184 species under threat. The remaining ASEAN nations were ranked: Malaysia, 7; Vietnam, 12; Myanmar, 14; Laos, 15; The Philippines, 19; Cambodia, 20; Brunei, 25; Singapore, 93, of 214 countries.
Emus forage in a diurnal pattern and eat a variety of native and introduced plant species. The diet depends on seasonal availability with such plants as Acacia, Casuarina and grasses being favoured. They also eat insects and other arthropods, including grasshoppers and crickets, beetles, cockroaches, ladybirds, bogong and cotton-boll moth larvae, ants, spiders and millipedes. This provides a large part of their protein requirements. In Western Australia, food preferences have been observed in travelling emus; they eat seeds from Acacia aneura until the rains arrive, after which they move on to fresh grass shoots and caterpillars; in winter they feed on the leaves and pods of Cassia and in spring, they consume grasshoppers and the fruit of Santalum acuminatum, a sort of quandong. They are also known to feed on wheat, and any fruit or other crops that they can access, easily climbing over high fences if necessary. Emus serve as an important agent for the dispersal of large viable seeds, which contributes to floral biodiversity. One undesirable effect of this occurred in Queensland in the early twentieth century when emus fed on the fruit of prickly pears in the outback. They defecated the seeds in various places as they moved around, and this led to a series of campaigns to hunt emus and prevent the seeds of the invasive cactus being spread. The cacti were eventually controlled by an introduced moth (Cactoblastis cactorum) whose larvae fed on the plant, one of the earliest examples of biological control.
== Composition == The prepreg matrix consists of a mixture of resin and hardener, in some cases an accelerator. Freezing at -20 °C prevents the resin from reacting with the hardener. If the cold chain is interrupted, the reaction starts and the prepreg becomes unusable. There are also high-temperature prepregs which can be stored for a certain time at room temperature. These prepregs can then be cured only in an autoclave at elevated temperature.
Sources: en.wikipedia.org
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.
No. It is a synthetic ligand that binds nuclear receptors, not a steroid or peptide hormone. Its activity depends on receptor binding rather than endocrine secretion.
Clinical evidence is limited. Most published data come from cell and animal experiments. Human safety and efficacy remain uncertain.
It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.